FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions can be used in treating cancer. Method of treating cancer in a subject involves combined administration to a subject in need thereof, 2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valineamide or its pharmaceutically acceptable salt and a PI3K-mTOR inhibitor selected from PF-384 and pharmaceutically acceptable salts thereof. Group of inventions also refers to a pharmaceutical composition, a dosage form and a kit for treating cancer in mammals.
EFFECT: group of inventions provides a synergetic effect on cell lines of lung cancer, breast cancer and ovarian cancer.
8 cl, 8 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION | 2014 |
|
RU2666921C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| PHARMACEUTICAL COMBINATION COMPRISING INHIBITOR PHOSPHATYLENOSITOL 3-KINASES AND AROMATASE INHIBITOR | 2013 |
|
RU2651023C2 |
